The Lasker-DeBakey Award, often celebrated as “America’s Nobels,” honors extraordinary achievements in biomedical research with a strong clinical impact. Dr. Welsh shares this year’s honor with Jesús “Tito” González, formerly of Vertex Pharmaceuticals, and Paul A. Negulescu of Vertex Pharmaceuticals. Their collaborative work was vital in the creation of a novel triple-drug combination therapy that has revolutionized the treatment landscape for CF, extending life expectancy and managing symptoms with unprecedented efficacy.

Cystic fibrosis is a hereditary disorder caused by mutations in the CFTR gene, which encodes a protein crucial for the regulation of chloride ion transport across epithelial cell membranes. Proper chloride ion flow maintains the hydration of airway surfaces and facilitates the clearance of mucus that traps pathogens and particulates. CF-causing mutations impair the function of this CFTR protein, resulting in viscous, sticky mucus accumulation, chronic lung infection, and progressive tissue damage.

Welsh’s research deciphered key aspects of CFTR protein function and the detrimental effects of various mutations on chloride conductance. He demonstrated that defective CFTR disrupts ion transport, providing the scientific groundwork that made life-saving therapeutic interventions possible. This fundamental knowledge eventually spawned treatments that have shifted cystic fibrosis from a terminal illness in childhood to a chronic, manageable condition for many.

Starting his career over four decades ago, Welsh’s early investigations focused on airway epithelial ion transport abnormalities in CF patients, a subject that preceded the identification of the CF gene in 1989. His team conclusively established that CFTR functions as an ion channel that permits chloride movement across airway surfaces, a breakthrough that deepened understanding of the disease’s pathophysiology. Moreover, Welsh’s lab made the seminal observation that lowered temperatures could “correct” certain mutant CFTR proteins, hinting at the possibility of pharmacological agents capable of restoring CFTR function.

This pivotal insight gave rise to intensive drug discovery efforts aimed at finding small molecules capable of rescuing dysfunctional CFTR variants. Welsh’s categorical classification of CFTR mutations into mechanistic groups allowed for targeted therapeutic development, as specific drugs could be designed to address distinct functional defects. Vertex Pharmaceuticals, leveraging innovative high-throughput screening technologies initiated in part by González and Negulescu, identified compounds that potentiated or corrected CFTR activity.

The culmination of these efforts was the approval of Trikafta® in 2019, a triple-combination therapy that simultaneously addresses multiple categories of CFTR mutations. This therapy dramatically improves chloride channel function and lung health for roughly 90% of individuals with CF, markedly extending life expectancy from a mid-30s average for those born two decades ago to projections approaching eight decades for newborns today.

Welsh emphasizes that scientific progress of this magnitude rests on multidisciplinary collaboration, institutional support, and sustained funding—both public and private. He underscores the importance of curiosity-driven fundamental science as the foundation from which transformative clinical innovations can emerge. His career is a testament to the power of perseverance and the impact of discovery-driven medicine.

While the advances in CF treatments have been extraordinary, Welsh cautions that challenges remain. Approximately 10% of people with CF harbor mutations that do not yet respond to existing therapies. The scientific community must continue dissecting molecular mechanisms and developing novel interventions tailored to these patient populations, ensuring that no individual is left behind in the quest to conquer cystic fibrosis.

Welsh’s extensive career includes numerous accolades recognizing his contributions to CF research and clinical medicine. Beyond the Lasker Award, he has received honors such as the Steven C. Beering Award, Warren Alpert Foundation Prize, Shaw Prize in Life Sciences & Medicine, the Canada Gairdner International Award, and more. His leadership roles have extended to presidencies of prominent societies and memberships in prestigious academies reflecting his stature as a leading physician-scientist.

An Iowa native, Welsh completed his undergraduate education, medical training, and residency at the University of Iowa, joining its faculty in 1981. He holds numerous academic appointments within the Carver College of Medicine, directing the Pappajohn Biomedical Institute while contributing to multiple departments. His tenure as an investigator at the Howard Hughes Medical Institute spanned decades of high-impact research.

The Lasker Awards themselves embody a rich legacy established in 1945 by Albert and Mary Lasker, visionary advocates of biomedical research. Celebrated annually, the awards recognize exceptional achievements in medical science that advance human health. Recipients are honored with a $250,000 prize at a ceremony held this year in New York City, underscoring the continuing global significance of the biomedical discoveries they celebrate.

Dr. Michael Welsh’s story is one of relentless dedication to understanding disease mechanisms at their most fundamental level and translating those insights into real-world therapies that save lives. His work vividly illustrates the potential of precision medicine and the remarkable outcomes achievable when scientific insight is harnessed with perseverance and collaboration.

Subject of Research: Cystic fibrosis molecular biology and therapeutic development
Article Title: Michael J. Welsh, MD, Awarded 2025 Lasker-DeBakey Award for Pioneering Cystic Fibrosis Research
News Publication Date: 2025
Web References: https://laskerfoundation.org/winners/combined-triple-drug-therapy-for-cystic-fibrosis/
Image Credits: University of Iowa Health Care
Keywords: Cystic fibrosis, CFTR protein, translational medicine, genetic disorders, clinical research, Lasker Award

Central to this breakthrough is the role of conventional type I dendritic cells (cDC1s), a subset of antigen-presenting cells known for their potent ability to orchestrate adaptive immune responses. Unlike broad immunotherapeutic strategies that primarily amplify existing immune activity, this approach purposefully initiates a novel, tumor-specific immune response. By extracting dendritic cells from tumor-bearing mice, loading them ex vivo with tumor-derived antigens, and subsequently reintroducing them into the same host, researchers have uniquely managed to activate cytotoxic T lymphocytes capable of targeting primary tumors and thwarting future relapses.

Dendritic cells serve as sentinels within the immune system, able to capture, process, and present tumor-associated antigens to naive T cells, thereby igniting a cascade of immune activation. However, dendritic cells comprise a heterogeneous population, and prior to this study, the precise subset best suited to evoke long-lasting anti-cancer immunity remained elusive. The CNIC-led research conclusively identifies cDC1s as the optimal subset for generating a strong and durable immune memory response crucial to sustained tumor control.

Ignacio Heras-Murillo, the study’s first author and a researcher at CNIC, emphasizes the significance of this work by highlighting its departure from conventional immunotherapies. Whereas current treatments often act by enhancing pre-existing immune responses, this novel strategy “induces a new, highly specific immune response against the tumor,” addressing one of the major hurdles in oncology: preventing tumor relapse after initial remission.

The innovative treatment protocol involves isolating type I dendritic cells directly from mice afflicted with cancer. These cells are then pulsed in vitro with tumor antigens, a process that effectively “educates” the dendritic cells to recognize malignant cell markers. Upon reinjection into the host, these cells engage and activate T lymphocytes, which target tumor cells with precision. Notably, this results not only in immediate tumor regression but also in the establishment of immunological memory capable of intercepting any subsequent tumor growth.

Stefanie Wculek, co-supervisor of the study and currently at IRB Barcelona, elaborates on the clinical implications of these findings. The dual effect of the therapy — combining rapid tumor elimination with long-lasting immune vigilance — offers an encouraging framework for designing next-generation cancer immunotherapies capable of durable remission, a goal that has remained challenging for decades.

The study’s principal investigator, CNIC scientist David Sancho, underscores the ability of the cDC1-based immunotherapy to prevent tumor relapse by inducing immune memory. According to Sancho, this memory response effectively “prevents the growth of a second, similar tumor” in the mouse models, highlighting the potential to avert metastatic progression and improve overall survival outcomes.

While these preclinical findings mark a significant milestone, the researchers acknowledge that additional studies are required to translate the approach from mouse models to human patients. Key questions include the therapy’s effectiveness against metastatic disease, compatibility with existing treatments such as immune checkpoint inhibitors, and scalability for clinical use.

This research was conducted with generous support from numerous institutions, including the CNIC, Spain’s Ministerio de Ciencia, Innovación y Universidades, the Agencia Estatal de Investigación, the European Union’s NextGenerationEU/PRTR initiative, the Comunidad de Madrid, the “la Caixa” Foundation, the Fundación Científica de la Asociación Española Contra el Cáncer, and Worldwide Cancer Research.

The CNIC itself is a leading cardiovascular research center affiliated with the Carlos III Health Institute and funded through public-private partnerships. Directed by Dr. Valentín Fuster, the center is renowned for its dedication to translating scientific discoveries into practical medical solutions and has been recognized by the Spanish government as a Severo Ochoa Center of Excellence.

Published in the journal Nature Communications, this cutting-edge investigation represents a paradigm shift in cancer immunotherapy by leveraging the unique properties of conventional type I dendritic cells. The ability to induce a specific, lasting immune response that actively prevents tumor relapse opens the door to novel therapeutic regimes that may dramatically improve patient outcomes across diverse cancer types.

The precision of this dendritic cell-based strategy directly addresses the challenges of immune evasion and tumor recurrence, offering hope for durable remission where traditional therapies have often fallen short. As the understanding of dendritic cell biology deepens, the prospect of personalized immunotherapies tailored to the immune landscape of each patient becomes increasingly attainable.

Looking ahead, further exploration of combination regimens incorporating cDC1 immunotherapy with other modalities, such as chemotherapy, radiation, or immune checkpoint blockade, could yield synergistic effects and widen the scope of clinical applicability. This study lays the foundational knowledge essential for such translational efforts, marking an exciting step toward more effective and durable cancer treatments.

Ultimately, the successful harnessing of type I dendritic cells to induce immune memory represents a significant advancement in the quest for cancer therapies that not only extinguish primary tumors but also fundamentally alter the immune system’s capacity to protect against future malignancies. This work exemplifies the power of immunological innovation in defeating cancer and underscores the critical importance of continued investment in cutting-edge biomedical research.

—

Subject of Research: People

Article Title: Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

News Publication Date: 9-Apr-2025

Web References:
– CNIC: https://www.cnic.es/en
– IRB Barcelona: https://www.irbbarcelona.org/es
– Nature Communications: https://www.nature.com/ncomms/
– DOI: http://dx.doi.org/10.1038/s41467-025-58289-1

Image Credits: CNIC

Keywords: Gene targeting, Primary tumors, Dendritic cells, Cancer immunotherapy, Immunological memory, Research organizations